US8980287B2ActiveUtilityPatentIndex 56
Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination
Est. expirySep 28, 2027(~1.2 yrs left)· nominal 20-yr term from priority
A61K 2039/53A61K 2039/55522A61P 31/00C12Y 207/10001A61K 45/06A61K 31/704C12N 9/12A61P 35/00A61K 39/001162A61K 39/0011A61K 2300/00
56
PatentIndex Score
3
Cited by
33
References
5
Claims
Abstract
Use of intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein and/or a nucleic acid molecule encoding for the intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein, of any species, for the preparation of a medicament, preferably a vaccine, for the treatment and/or prevention of a tumor in a subject, preferably a lymphoma.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A method of treating or delaying the growth of an Anaplastic Lymphoma Kinase (ALK) protein expressing tumor comprising administering to a subject in need thereof a purified nucleic acid molecule comprising,
i) a nucleotide sequence selected from the group consisting of the nucleotide of SEQ ID No.:2 encoding the intracytoplasmatic domain of an ALK protein lacking a tyrosine kinase domain and the nucleotide of SEQ ID NO.: 3, encoding the intracytoplasmatic domain of an ALK protein comprising an inactivating mutation in the catalytic domain; or
ii) a nucleic acid sequence encoding the amino acid of SEQ ID NO.: 5, which is the intracytoplasmic domain of an ALK protein;
wherein said purified nucleic acid molecule is administered in a therapeutically effective amount to treat or delay tumor growth.
2. The method according to claim 1 , wherein the nucleic acid molecule is administered in combination with a nucleic acid molecule encoding Granulocyte-Monocytes Colony Stimulating Factor (GM-CSF).
3. The method according to claim 1 , wherein the amino acid sequence of said intracytoplasmatic domain of said ALK protein is the amino acid sequence of the intracytoplasmatic domain of human ALK protein.
4. The method according to claim 1 , wherein the tumor is a neuroblastoma, a glioblastoma, a soft tissue tumor, an ALK expressing lymphoma, an ALK expressing lung, breast, colon or prostate carcinoma.
5. The method according to claim 1 , wherein the nucleic acid molecule is present in a plasmid.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.